Strong sales of drugs, vaccines, propel Merck in third quarter
Revenue rose to $12.55B from $12.4B
KENILWORTH, N.J. — Merck & Co. is reporting third-quarter earnings of $2.94 billion on some very strong sales.
OXFORD, ASTRAZENECA VACCINE SHOWS PROMISING IMMUNE RESPONSE IN OLDER ADULTS
The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| MRK | MERCK & CO. INC. | 127.02 | +0.08 | +0.06% |
That easily topped Wall Street expectations for earnings of $1.44 per share, according to a survey of analysts by Zacks Investment Research.
Revenue of $12.55 billion, also easily beating analyst projections for $12.26 billion.
Merck expects full-year earnings in the range of $5.91 to $6.01 per share, with revenue in the range of $47.6 billion to $48.6 billion.
GILEAD WINS FIRST FDA OK FOR COVID-19 VACCINE
Merck shares have dropped 13% since the beginning of the year, while the Standard & Poor’s 500 index has climbed slightly more than 5%. The stock has declined 4.5% in the last 12 months.